•  
  •  
  •  
  •  

2025-10-02 17:46:39

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  OralSuspension

Stock Report

  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • ZIM Laboratories Ltd announces grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe
  • Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension
  • Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension
  • Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension
  • Lupin launches Rufinamide Oral Suspension in the United States
  • Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension
  • Glenmark Pharmaceuticals Ltd updates on Baddi facility
  • Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
  • Lupin Launches Sildenafil for Oral Suspension in the United States
  • Strides receives USFDA approval for Ibuprofen OTC Oral Suspension
  • Strides receives USFDA approval for Ibuprofen Oral Suspension
  • Lupin receives approval from U.S. FDA for Sildenafil for Oral Suspension
  • Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024